Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
of the tumour came to T4N2M1a according to 8th edition of IASLC TNM
classification for lung cancer. Her performance status improved to ECOG 2.
She was given cisplatin and etoposide in addition to brain radiation therapy.
Conclusion: The second primary malignancy refers to a different type of
cancer in a person who has survived an earlier cancer. There are series of nonsmall
cell lung cancer (NSCLC) reported as second primary after breast cancer.
To our knowledge, this is the first case presented as small cell lung cancer as
second malignancies in lung in a fully treated breast cancer patient. This may
be related risk of second malignancies associated with radiotherapy exposure
to lung applied for breast cancer or due to adjuvant treatment as in this case.
Keywords: Second primary SCLC lung breast cancer
POSTER SESSION 1 - P1.07: SCLC/NEUROENDOCRINE TUMORS
SCLC/NEUROENDOCRINE TUMORS IN GENERAL –
MONDAY, DECEMBER 5, 2016
P1.07-055 INTRODUCING THE US NATIONAL CANCER INSTITUTE’S
SMALL CELL LUNG CANCER CONSORTIUM
Peter Ujhazy, Eva Szabo, Suzanne Forry
National Cancer Institute, Rockville/MD/United States of America
Background: Small cell lung cancer (SCLC) remains a major clinical challenge,
however recent discoveries and early positive signals in clinical trials are
promising more optimistic outcomes for patients with this disease. The
United States National Cancer Institute (NCI) launched in December 2015
a series of solicitations for grant applications with the goal to establish a
SCLC consortium. The Consortium will address five strategic priority areas
established by an international group of experts and the NCI. These areas
are: 1. Better research tools for the Study of SCLC, 2. Comprehensive genomic
profiling of SCLC, 3. New diagnostic and prevention approaches for SCLC, 4.
Therapeutic development efforts, and 5. Mechanisms underlying both high
rate of initial response and rapid emergence of drug and radiation resistance.
The initiative for early detection and prevention of SCLC is now open for
potential applicants through 2017 (PAR-16-51); applications for therapy and
mechanism of resistance projects can be submitted through 2018 (PAR-16-49).
Methods: Section not applicable Results: (Note: The first round of application
was reviewed right before the IASLC abstract submission deadline, funding
decisions will be made in early November 2016, so by the time of the November
11 deadline for the poster submission we will be able to include the first funded
projects in the consortium in the abstract and in the poster.) Conclusion:
Section not applicable
Keywords: Therapy, Early Detection, small cell lung cancer, drug resistance
POSTER SESSION 1 - P1.08: SURGERY
Risk Assessment & Prognostic Factors –
MONDAY, DECEMBER 5, 2016
P1.08-001 LOG ODDS AS A NOVEL PROGNOSTIC INDICATOR
SUPERIOR TO THE NUMBER-BASED AND RATIO-BASED CATEGORY
FOR NON-SMALL CELL LUNG CANCER
Dariusz Dziedzic, Piotr Rudzinski, Tadeusz Orlowski
Thoracic Surgery, National Institute of Chest Diseases, Warsaw, Poland, Warsaw/
Poland
Background: The paper aimed to compare the efficacy of log odds (LODDS)
compared to a classification based on the number of positive lymph
nodes (pN) and lymph node ratio (LNR). Methods: Material was collected
retrospectively from an online survey-based database of the Polish Lung
Cancer Group and included a group of 17369 patients who received radical
surgical treatment (R0) due to lung cancer. The follow-up period was between
11.4 and 66.0 months (median 30.1 months). Results: In the whole group the
median survival for N0, N1 and N2 was 76.1, 41.7 and 24.2 months, respectively.
The median survival for individual LODDS categories (-6,-4], (-4,-3], (-3,-2],
(-2,-1], (-1,0], (0,1] and (1,2] was 76.5, 76.3, 71.7, 45.4, 25.0, 19.1 and 17.7 months,
respectively. The median survival for LNR in individual categories (0), (0,0.25],
(0.25,05], (0.5,075] and (0.75,1.0] was 75.6, 40.3, 24.1, 18.8 and 16.4 months,
respectively. When comparing LODDS and LNR significant heterogeneity
can be seen that is especially visible in categories (0), (0,0.25] LNR, where 4
LODDS categories were distinguished. A multi-variant analysis demonstrated
that each LODDS category is an independent prognostic factor: (-4,-3] (HR =
0.982; 95% CI 0.867-1.112; P = 0.775), (-3,-2] (HR = 1.114; 95% CI 0.984-1.262; P =
0.089), (-2,-1] (HR = 1.241; 95% CI 1.080-1.425; P = 0.002), (-1,0] (HR = 1.617; 95%
CI 1.385-1.887; P < 0.0001), (0,1] (HR = 1.918; 95% CI 1.579-2.329; P < 0.0001)
and (1,2] (HR = 2.016; 95% CI 1.579-2.573; P < 0.0001). Conclusion: Based on
LODDS it is possible to discriminate patients with regard to lung cancer stage
more effectively compared to pN and LNR classification, and it is also a better
classification system. Therefore, a new system of lung cancer classification
based on LODDS should be considered.
POSTER SESSION 1 - P1.08: SURGERY
RISK ASSESSMENT & PROGNOSTIC FACTORS –
MONDAY, DECEMBER 5, 2016
P1.08-002 THE PROGNOSTIC SIGNIFICANCE OF PLEURAL LAVAGE
CYTOLOGY BEFORE AND AFTER LUNG RESECTION
Yohei Yurugi, Yoshiteru Kidokoro, Takashi Ono, Yasuaki Kubouchi, Makoto
Wakahara, Ken Miwa, Kunio Araki, Yuji Taniguchi, Hiroshige Nakamura
General Thoracic Surgery, Tottori University, Yonago/Japan
Background: The status of intraoperative pleural lavage cytology (PLC) has
been reported to be a predictive factor of recurrence in resected non-small
cell lung cancer (NSCLC). However, prognostic significance of PLC remains
unclear and it has not been included in the TNM classification. Furthermore,
the appropriate timing to perform PLC, before lung resection (pre-PLC) or
after lung resection (post-PLC), is not evident. Methods: Of 627 consecutive
patients with NSCLC who underwent complete resection (segmentectomy
or more) in Tottori University Hospital from January 2004 to December 2013,
615 patients who were performed both pre-PLC and post-PLC were enrolled
in present study. Patients were divided into four groups, negative pre-PLC /
negative post-PLC (Group A), positive pre-PLC / negative post-PLC (Group B),
negative pre-PLC / positive post-PLC (Group C), and positive pre-PLC / positive
post-PLC (Group D). Then differences in recurrence free survival (RFS) and
disease specific survival (DSS) among each groups were analyzed by log-rank
test. Moreover, PLC status as a prognostic factor for RFS and DSS were
analyzed using univariate and multivariate Cox regression models. Results:
There were 573 patients in Group A, 11 in Group B, 14 in Group C, and 17 in
Group D, respectively. Survival analysis revealed significant differences in not
only RFS but also DSS between Group A and Group B (log-rank test, p